Jounce Therapeutics to Participate in the Upcoming Investor Conferences
On September 7, 2022, Jounce Therapeutics (NASDAQ: JNCE) announced participation in two investor conferences in New York this September.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
On September 7, 2022, Jounce Therapeutics (NASDAQ: JNCE) announced participation in two investor conferences in New York this September. The company will engage in a fireside chat at the H.C. Wainwright 24th Annual Global Investment Conference on September 12 at 10:00 a.m. ET and participate in a panel at the Cantor Oncology Conference on September 28 at 2:35 p.m. ET. Interested parties can access the webcasts via Jounce’s website, with replays available for 30 days.
Jounce focuses on cancer immunotherapy and has several promising therapeutic candidates in development.
Details
News Market Reaction – JNCE
The recorded move for JNCE in the trading session of this news was +2.00%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMBRIDGE, Mass., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that company management will participate in the following upcoming investor conferences in September:
- H.C. Wainwright 24th Annual Global Investment Conference: Fireside chat on Monday, September 12, 2022 at 10:00 a.m. ET in New York, NY.
- Cantor Oncology, Hematology & HemeOnc Conference: Panel titled, “Tackling the Tumor Microenvironment and Further Arming the Immune System” on Wednesday, September 28, 2022 at 2:35 p.m. ET in New York, NY.
A webcast of the presentations will be available by visiting “Events and Presentations” in the Investors and Media section of Jounce’s website at www.jouncetx.com. A replay of the webcasts will be archived for 30 days following the presentation.
About Jounce Therapeutics
Jounce Therapeutics, Inc. is a clinical-stage immunotherapy company dedicated to transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long-lasting benefits to patients through a biomarker-driven approach. Jounce currently has multiple development stage programs ongoing while simultaneously advancing additional early-stage assets from its robust discovery engine based on its Translational Science Platform. Jounce’s highest priority program, JTX-8064, is a LILRB2 (ILT4) receptor antagonist shown to reprogram immune-suppressive tumor associated macrophages to an anti-tumor state in preclinical studies. JTX-8064 is being investigated alone and in combination with pimivalimab (formerly JTX-4014), Jounce’s internal PD-1 inhibitor, in one monotherapy and seven indication-specific combination therapy cohorts in the Phase 1/2 INNATE trial and is currently enrolling patients with advanced solid tumors in the Phase 2 portion of the study. Jounce’s most advanced product candidate, vopratelimab, is a monoclonal antibody that binds to and activates ICOS, and is currently being studied in the SELECT Phase 2 trial. Pimivalimab is a PD-1 inhibitor intended for combination use in the INNATE and SELECT trials and with Jounce’s broader pipeline. Additionally, Jounce exclusively licensed worldwide rights to GS-1811 (formerly JTX-1811), a monoclonal antibody targeting CCR8 and designed to selectively deplete T regulatory cells in the tumor microenvironment, to Gilead Sciences, Inc. For more information, please visit www.jouncetx.com.
Investor and Media Contact:
Eric Laub
+1-857-259-3853
elaub@jouncetx.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.